CRNX

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

After Crinetics' $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?

Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)

Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?

Stifel cuts Crinetics stock rating to hold on Vertex acquisition

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now?

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.

Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.

Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout

Crinetics Pharmaceuticals director sells $120,000 in stock